Clostridium Difficile Infection in the Nephrology Ward

Dudzicz, Sylwia; Adamczak, Marcin; Wiȩcek, Andrzej

doi:10.1159/000484428

Cited by 10 publications

(7 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…C. difficile is currently the most frequently identified pathogen involved in the development of AAD (Dudzicz et al, 2017). Infections by other microbes, such as Staphylococcus aureus and Clostridium perfringens have also been identified as causes (Boyce and Havill, 2005;Modi and Wilcox, 2001).…”

Section: Clostridioides Difficilementioning

confidence: 99%

Lactiplantibacillus plantarum 299v (LP299V®): three decades of research

Nordström

Teixeira

Montelius

et al. 2021

View full text Add to dashboard Cite

This review aims to provide a comprehensive overview of the in vitro, animal, and clinical studies with the bacterial strain Lactiplantibacillus plantarum 299v (L. plantarum 299v; formerly named Lactobacillus plantarum 299v) published up until June 30, 2020. L. plantarum 299v is the most documented L. plantarum strain in the world, described in over 170 scientific publications out of which more than 60 are human clinical studies. The genome sequence of L. plantarum 299v has been determined and is available in the public domain (GenBank Accession number: NZ_LEAV01000004). The probiotic strain L. plantarum 299v was isolated from healthy human intestinal mucosa three decades ago by scientists at Lund University, Sweden. Thirty years later, a wealth of data coming from in vitro, animal, and clinical studies exist, showing benefits primarily for gastrointestinal health, such as reduced flatulence and abdominal pain in patients with irritable bowel syndrome (IBS). Moreover, several clinical studies have shown positive effects of L. plantarum 299v on iron absorption and more recently also on iron status. L. plantarum 299v is safe for human consumption and does not confer antibiotic resistance. It survives the harsh conditions of the human gastrointestinal tract, adheres to mannose residues on the intestinal epithelial cells and has in some cases been re-isolated more than ten days after administration ceased. Besides studying health benefits, research groups around the globe have investigated L. plantarum 299v in a range of applications and processes. L. plantarum 299v is used in many different food applications as well as in various dietary supplements. In a freeze-dried format, L. plantarum 299v is robust and stable at room temperature, enabling long shelf-lives of consumer healthcare products such as capsules, tablets, or powder sachets. The strain is patent protected for a wide range of indications and applications worldwide as well as trademarked as LP299V®.

show abstract

Section: Clostridioides Difficilementioning

confidence: 99%

Lactiplantibacillus plantarum 299v (LP299V®): three decades of research

Nordström

Teixeira

Montelius

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Другим фактором риска диареи, ассоциированной с CD-инфекцией, явилось проведение заместительной терапии в виде хронического гемодиализа (ОШ 8,64; 95% ДИ 1,05-70,81). Повышенный риск CD-инфекции у пациентов с терминальной стадией хронической болезни почек может быть вызван частым проведением антибиотикоте-рапии в связи с многочисленными инфекциями, что приводит к дисфункции кишечной микрофлоры [8,18]. Другими неблагоприятными факторами у данной категории пациентов могут быть частые госпитализации в круглосуточный стационар и изменения в иммунной системе, в частности, нарушение функции Т-лимфоцитов, моноцитов, нейтрофилов, дендритных клеток и дисбаланс в секреции цитокинов [19].…”

Section: факторы рискаunclassified

Risk Factors for diarrhea associated with Clostridium difficile in patients at a clinical hospital

Yarushina

Колотова

Руднов

et al. 2019

Terapevticheskii arkhiv

View full text Add to dashboard Cite

Aim: to identify risk factors for Clostridium difficile infection in patients of a therapeutic clinic in a multidisciplinary hospital. Materials and methods. A retrospective analysis of 110 case histories of patients who were hospitalized in therapeutic departments in the Municipal Autonomous Institution “City Clinical Hospital No. 40” in Yekaterinburg (MAU City Clinical Hospital No. 40) in 2014-2015 was conducted, in which antibiotic therapy has developed diarrhea. According to the results of the study of coprofiltrate on Clostridium difficile (CD), patients were divided into 2 groups: 60 patients with a positive result and 50 patients with a negative result. Results. The proportion of patients with CD infection in the structure of patients of the therapeutic profile of the MAU GKB No.40 for 2014-2015 amounted to 0.42%. Predictors of the risk of developing diarrhea associated with CD infection in patients are: age over 65 years (OS 4.33, 95% CI 1.15-16.20, p=0.028), Charlson comorbidity index more than 2 points (OS 3.05, 95% CI 1.29-7.23, p=0.016), the presence of anemia (OR 2.32, 95% CI 1.07-5.02, p=0.048), chronic dialysis in patients with chronic renal insufficiency (CRF) (OR 8.64, 95% CI 1.05-70.81, p=0.020), patients staying in hospital for more than 5 days (OR 3.50, 95% CI 1.57-7.75, p=0.003) and hospitalization of patients in the intensive care unit (ICU) lasting more than 1 day (OS 9.80, 95% CI 1.20-79.47, p=0.011), the use of proton pump inhibitors (PPIs) (OR 2.82, 95% CI 1.12-7.11, p=0.041), antibiotic therapy more than 10 days (OS 39.62, 95% CI 10.85-144.71, p

show abstract

“…Older age, antibiotic exposure and hospitalization have been described as major risk factors for C. difficile acquisition [ 10 , 11 , 12 ]. Other risk factors for CDI are immunosuppression, prolonged PPI use, chronic kidney disease, use of nasogastric tubes, and gastrointestinal surgery [ 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 ]. The new onset of unexplained diarrhea, especially in vulnerable categories of patients, with more than three unformed stools in 24 h, requires CDI testing for appropriate therapy [ 21 ].…”

Section: Introductionmentioning

confidence: 99%

The Impact of Clostridioides Difficile Infection in Hospitalized Patients: What Changed during the Pandemic?

et al. 2022

View full text Add to dashboard Cite

(1) Background: Clostridioides difficile (C. difficile) and SARS-CoV-2 coronavirus represent significant health threats. Our study focused on the impact of concurrent infections on patient outcomes against the backdrop of changes imposed by the pandemic. (2) Materials and methods. We performed a retrospective analysis and included patients diagnosed with CDI who were admitted in our hospital before and during the pandemic. We compared patient exposure to risk factors for CDI in both groups and patient negative outcomes: need for ICU care, prolonged hospitalization, organ failure, toxic megacolon, and death. (3) Results. Overall, 188 patients were included, of which 100 had CDI (the pre-pandemic group), and 88 patients presented both CDI and COVID-19 (the pandemic group). Patients in the pandemic group were significantly older, with a higher Charlson Comorbidity Index (CCI) and a greater exposure to antibiotics and corticosteroids, and were more likely to develop organ dysfunction, to require ICU care and have prolonged hospitalization. The severity of COVID-19, leukocytosis and increased D-dimer levels were indicators of poor prognosis in the pandemic group. Higher CCI scores and leukocytosis increased the risk for negative outcomes in CDI alone patients. (4) Conclusions. The study highlights the negative impact of associated infections on patient outcome. The severity of COVID-19 directly influences the prognosis of patients with concurrent infections

show abstract

Clostridium Difficile Infection in the Nephrology Ward

Cited by 10 publications

References 39 publications

Lactiplantibacillus plantarum 299v (LP299V®): three decades of research

Lactiplantibacillus plantarum 299v (LP299V®): three decades of research

Risk Factors for diarrhea associated with Clostridium difficile in patients at a clinical hospital

The Impact of Clostridioides Difficile Infection in Hospitalized Patients: What Changed during the Pandemic?

Contact Info

Product

Resources

About